On July 15, 2019, Inspyr Therapeutics, Inc. (the Company) was informed by Christopher Lowe, that he is resigning as chief executive officer, chief, financial officer, president, and as a member of the board of directors (Board) of the Company. Mr. Lowe's resignation did not result from any disagreement with the Company on any matter relating to its operations, policies or practices. On July 26, 2019, the Company appointed Michael Cain to serve as the interim chief executive officer, chief financial officer, president, and as a member of the Board.

Mr. Cain will serve on an interim basis as principal executive and financial officer on an at-will basis. Michael Cain, 35 has over 15 years of experience in technology and computer consulting fields. Mr. Cain serves as the President and as a Board member of Level 4 Services, Inc. since 2013.

In evaluating Mr. Cain's specific experience, qualifications, attributes and skills in connection with his appointment to Board, the company took into account his management experience in other organizations and business development background.